Pulse Biosciences, Inc., a clinical-stage medical technology company headquartered in Hayward, California, disclosed in a US Securities and Exchange Commission filing that the company and several of its directors have received subpoenas from the SEC. According to Pulse, the SEC is seeking information about trading of the company’s stock in advance of the financing announcement made by the company in September 2017. Pulse says that it is cooperating with the investigation.
March 14, 2019
Medical technology company discloses SEC investigation
Related by Topic
New Post
SEC settles with California resident to resolve insider trading charges
March 12, 2023
News Alert
New Post
SEC charges healthcare executive with insider trading in connection with two Rule 10b5-1 trading plans
March 6, 2023
News Alert
New Post
SEC charges private equity consultant and his close friend with insider trading
February 28, 2023
News Alert